A post-marketing study on Interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 74, Issue 12, 2003, Pages 1689-1692

  Milanese, C ^a,h   La Mantia, L ^a   Palumbo, R ^a   Martinelli, V ^b   Murialdo, A ^c   Zaffaroni, M ^d   Caputo, D ^e   Capra, R ^f   Bergamaschi, R ^g  

^a Ist Nazionale Neurologico C Besta   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Ospedale di Gallarate   (Italy)

^e Centro Sclerosi Multipla   (Italy)

^f Ospedale Civile di Brescia   (Italy)

^g C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^h DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISABILITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; INCIDENCE; ITALY; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; DISABILITY EVALUATION; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; ITALY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT DROPOUTS; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; TREATMENT OUTCOME;

EID: 0348012903     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.12.1689     Document Type: Article

References (12)

1. Autorizzazione alla immissione in commercio della specialità medicinale Betaferon. Decreto Ministeriale del 5/2/1996. Gazzetta Uff 41, del 19/2/ 96.
2. Autorizzazione alla immissione in commercio della specialità medicinale Avonex. Decreto Ministeriole UAC/C/n 17/1997; 8/8/98. Gazzetta Uff 186, del 11/8/9.
3. Goodkin DE, Kanoti G. Ethical considerations raised by the approval of interferon beta 1b for the treatment of multiple sclerosis. Neurology 1994;44:166-70.
4. Huber S, Spycher M, Lechner-Scott J, et al. Therapie mit rekombinantem Interferon beta 1b. Schweiz Med Wochenschr. 1996;126: 1475-81. [In German.]
5. Anonymous. Interferon beta-1b in the treatment of relapsing-recurrent multiple sclerosis. Clinical experience of the Valencia group.Multiple sclerosis study group of the city of Valencia. Rev Neurol. 1997;25: 1876-9. [In Spanish.]
6. Arbizu T, Alvarez-Cermelo IC, et al. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 2000;162:209-17.
7. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon beta. Eur J Neurol 2002;9:645-55.
8. Khan OA, Tselis AC, Kamholz JA, et al. A prospective open-label treatment trial to compare the effect of IFN beta-1a(Avonex), IFN beta-1b (Betaferon) and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001;8:141-8.
9. Durelli I, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once weekly interferon beta 1 a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002;359:1453-60.
10. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
12. The IFNB Multiple Sclerosis Study Group and the University of British Columbia. MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial, Neurology 1995;45:1277-85.